Evidence map›Paper›PMID 42337043›Full record

Trial reportBritish journal of cancer2026

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Jiajia Yuan, Jifang Gong, Zhi Peng, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Yusheng Wang and 7 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05019794 (A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05019794 phase2unknown statusnot on this map

A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations

TypeinterventionalSponsorLianBio LLCRan2020 to 2023Enrolled80ConditionsGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid TumorArmsInfigratinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jiajia Yuan *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Jifang Gong *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.ORCID http://orcid.org/0000-0003-3798-7024
Zhi Peng *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Tian Shu LiuMedical Oncology Department, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
HuiTing XuOncology Department, Hubei Cancer Hospital, Wuhan, China.
Jianwei YangClinical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China.
Jia WeiOncology Department, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.ORCID http://orcid.org/0000-0003-3024-8878
Haiping JiangMedicine Department, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China.
Yanhong DengClinical Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yusheng WangGastroenterology Ward One Department, Shanxi Cancer Hospital, Taiyuan, China.
Changsong QiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, China.ORCID http://orcid.org/0000-0001-9157-3768
Cheng LyuClinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.
Qiao SunClinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.
Lei MuClinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.
Lin SongClinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.
Xiaotian ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. zhangxiaotian@bjmu.edu.cn.
Lin ShenState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. shenlin@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-1134-2922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFGFR2 has garnered attention as a promising therapeutic target for gastric cancer (GC) because of its role in GC progression. Infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, has shown potential in preclinical GC models.

methodsInfigratinib was evaluated in a phase 2 trial for patients with FGFR2-amplified GC or gastroesophageal junction (GEJ) adenocarcinoma who had failed two or more lines of systemic treatment for locally advanced or metastatic disease. A total of 21 patients received 125 mg of infigratinib orally once daily on a "3 weeks on, 1 week off" schedule.

resultsInfigratinib showed preliminary antitumor activity in this molecularly selected population, as reflected by a confirmed objective response rate of 23.8% (95% CI, 8.2-47.2) with median progression-free survival of 3.4 months and median overall survival of 6.7 months. The most common grade 3-4 adverse events were elevated aspartate aminotransferase, decreased white blood cell count, and neutropenia. No treatment-related deaths occurred. Exploratory genomic analyses identified alterations in individual patients with disease progression that may be associated with resistance; however, these findings were based on a limited number of cases and should be interpreted as hypothesis-generating.

conclusionsThe findings support continued investigation of FGFR-targeted strategies in FGFR2-amplified GC/GEJ adenocarcinoma, while underscoring the need for larger studies, refined biomarker selection, and deeper characterization of resistance mechanisms.

trial registrationNCT05019794, Registered 28 July 2021, https://clinicaltrials.gov/study/NCT05019794 .

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionPyrimidinesReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdultAgedFemaleGene AmplificationHumansMaleMiddle AgedPhenylurea CompoundsFGFR2 protein, humaninfigratinibPhenylurea CompoundsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID42337043
PMCPMC13534696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.